Immune modulation with glp-1 receptor agonists: A breakthrough in treatment.

Purnima Das*

Department of Epidemiology, University of Michigan, School of Public Health, MI, United States

Introduction

In recent years, the field of immunology has seen significant advancements, one of the most promising being the potential role of GLP-1 receptor agonists (GLP-1RAs) in immune modulation. While GLP-1 receptor agonists have long been used to manage type 2 diabetes and obesity due to their ability to regulate blood sugar and reduce body weight, emerging research suggests that these drugs may have broader implications, particularly in modulating the immune system. This breakthrough could pave the way for novel therapeutic strategies in treating autoimmune diseases, chronic inflammation, and even cancer [1].

Glucagon-like peptide-1 (GLP-1) is a hormone that plays a critical role in regulating glucose metabolism, insulin secretion, and appetite. GLP-1 receptor agonists are synthetic compounds that mimic the action of GLP-1 by binding to its receptors, thereby enhancing insulin secretion in response to meals, slowing gastric emptying, and promoting satiety. The use of GLP-1RAs like liraglutide, semaglutide, and exenatide has revolutionized the management of type 2 diabetes and obesity, with additional benefits in cardiovascular health [2].

These agents are primarily known for their metabolic effects, but their interaction with the immune system has only recently been explored. Researchers have identified that GLP-1 receptors are expressed not only in pancreatic beta cells but also in various immune cells, including T-cells, macrophages, and dendritic cells. This discovery has led scientists to investigate the immune-modulating properties of GLP-1RAs in the context of both autoimmune diseases and inflammatory conditions [3].

One of the key areas where GLP-1RAs are showing promise is in autoimmune diseases, where the immune system mistakenly attacks the body's own tissues. Conditions like rheumatoid arthritis, multiple sclerosis, and type 1 diabetes are characterized by chronic inflammation and immune dysregulation. Research suggests that GLP-1RAs may help modulate the immune response, potentially reducing the harmful inflammation associated with these diseases [4].

GLP-1RAs have been found to influence the activity of various immune cells. For instance, in preclinical studies, GLP-1RAs have been shown to alter T-cell differentiation and function. T-cells, particularly Th17 cells, play a central role in autoimmune diseases, promoting inflammation. GLP-1RAs appear to reduce the differentiation of Th17 cells, potentially leading to a decrease in the inflammatory processes that drive autoimmune attacks. Additionally, GLP-1RAs seem to enhance the function of regulatory T-cells (Tregs), which are responsible for suppressing harmful immune responses and maintaining immune tolerance [5].

GLP-1RAs also appear to impact the production of pro-inflammatory cytokines, which are signaling molecules that drive immune responses. Inflammatory cytokines such as TNF-alpha, IL-6, and IL-1 beta are often elevated in autoimmune diseases and chronic inflammation. Studies have shown that GLP-1RAs can reduce the levels of these cytokines, suggesting that they may play a role in dampening the inflammatory environment that exacerbates disease symptoms [6].

Macrophages and dendritic cells are critical components of the immune system, responsible for recognizing and presenting pathogens to other immune cells. GLP-1Rs are expressed on these cells, and their activation has been shown to alter their behavior. GLP-1RAs may modulate the function of these cells, potentially reducing the immune system's overactive responses that contribute to autoimmune disease progression [7].

Given the immune-modulating properties of GLP-1RAs, researchers have begun exploring their potential in treating autoimmune diseases. One notable example is type 1 diabetes, where the immune system attacks insulin-producing beta cells in the pancreas. In animal models of type 1 diabetes, GLP-1RAs have shown the ability to preserve beta-cell function and reduce inflammation within the pancreas. This suggests that GLP-1RAs could complement traditional treatments by modifying the immune response and possibly slowing disease progression [8].

Rheumatoid arthritis (RA) is another autoimmune condition that may benefit from immune modulation via GLP-1RAs. Chronic inflammation in RA leads to joint destruction and pain. Early studies indicate that GLP-1RAs can help reduce inflammation in animal models of RA, potentially providing a new approach to managing this debilitating disease. While more research is needed to confirm these findings in humans, the early results are promising [9].

***Correspondence to :** **Purnima Das**, Department of Epidemiology, University of Michigan, School of Public Health, MI, United States. E-mail: prnma@das

***Received:** 30-Aug-2024, Manuscript No. AADY-25-158383; **Editor assigned:** 02- Sep -2024, PreQC No. AADY-25-158383(PQ); **Reviewed:** 11- Sep -2024, QC No. AADY-25-168383;**Revised:** 16-Sep-2024, Manuscript No. AADY-25-158383; **Published:** 25- Sep -2024, DOI: 10.36841/aady-8.5.229*

***Citation:** Das P: Immune modulation with glp-1 receptor agonists: A breakthrough in treatment. J Diabetol. 2024;8(5):229*

In addition to autoimmune diseases, GLP-1RAs could have therapeutic potential in conditions driven by chronic inflammation, such as atherosclerosis, cardiovascular disease, and even cancer. Chronic inflammation is a well-known contributor to cancer development, as it can create a tumor-friendly environment that promotes growth and metastasis. By modulating immune cell activity and reducing the production of pro-inflammatory cytokines, GLP-1RAs may help limit the inflammatory processes that underlie these diseases. Interestingly, some studies suggest that GLP-1RAs may also have direct antitumor effects. Animal studies have shown that GLP-1RAs can inhibit tumor growth in certain types of cancer, potentially offering a novel adjunct therapy for cancer treatment. While the clinical evidence is still limited, this line of investigation is generating considerable excitement in the scientific community [10].

Conclusion

The immune-modulating effects of GLP-1 receptor agonists represent an exciting breakthrough in medicine, extending the potential of these drugs beyond metabolic diseases to autoimmune disorders, chronic inflammation, and even cancer. By modulating the immune response, GLP-1RAs could offer new hope for patients with conditions that are traditionally difficult to treat. While much of the research is still in its early stages, the prospects for GLP-1RAs as a multifaceted therapeutic tool are undeniable. Further clinical studies will be essential to fully understand their potential and determine how best to integrate them into treatment protocols for a variety of immune-related conditions.

References

1. Hartman ZC, Appledorn DM, Amalfitano A. Adenovirus vector induced innate immune responses: impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus research. 2008 Mar 1;132(1-2):1-4.
2. Chang JH, Jiang Y, Pillarisetty VG. Role of immune cells in pancreatic cancer from bench to clinical application: an updated review. Medicine. 2016 Dec 1;95(49):e5541.
3. Look M, Bandyopadhyay A, Blum JS, Fahmy TM. Application of nanotechnologies for improved immune response against infectious diseases in the developing world. Advanced drug delivery reviews. 2010 Mar 18;62(4-5):378-93.
4. Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nature immunology. 2013 Dec;14(12):1212-8.
5. Soetaert F, Korangath P, Serantes D, Fiering S, Ivkov R. Cancer therapy with iron oxide nanoparticles: Agents of thermal and immune therapies. Advanced drug delivery reviews. 2020 Jan 1;163:65-83.
6. Jiang GM, Tan Y, Wang H, Peng L, Chen HT, Meng XJ, Li LL, Liu Y, Li WF, Shan H. The relationship between autophagy and the immune system and its applications for tumor immunotherapy. Molecular cancer. 2019 Dec;18:1-22.
7. Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal transduction and targeted therapy. 2023 Aug 28;8(1):320.
8. Nidetz NF, McGee MC, Longping VT, Li C, Cong L, Li Y, Huang W. Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. Pharmacology & therapeutics. 2020 Mar 1;207:107453.
9. Stevenson HC, Green I, Hamilton JM, Calabro BA, Parkinson DR. Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. Journal of clinical oncology. 1991 Nov;9(11):2052-66.
10. Sushnitha M, Evangelopoulos M, Tasciotti E, Taraballi F. Cell membrane-based biomimetic nanoparticles and the immune system: immunomodulatory interactions to therapeutic applications. Frontiers in bioengineering and biotechnology. 2020 Jun 17;8:627.

Citation: *Das P: Immune modulation with glp-1 receptor agonists: A breakthrough in treatment. J Diabetol. 2024;8(5):229*